(Opens in a new window)A review of life science current events reported by MedCity News this week:
J&J and Medtronic have contrasting acquisition strategies. Can both win? (Opens in a new window) J&J’s strategy of growing through acquisitions appears to contrast with the acquisition strategy of another top-tier CEO, who like Gorsky, is charged with a turnaround: Medtronic (NYSE:MDT) CEO Omar Ishrak.
Why a Medtronic executive wants rival Edwards Lifesciences to succeed. (Opens in a new window)“We need Edwards to succeed in transcatheter valve replacement,” Cornell told an audience gathered at the IBF MedTech Investing Conference in Minneapolis on Wednesday. “Success in a market floats all boats.”
(Opens in a new window)
The 5 Best Medical Billing Outsourcing Companies (Opens in a new window)
Medical billing is a tedious administrative task, but outsourcing it may be the key to increased revenue. Explore the top medical billing outsourcing companies and the benefits of partnering with one.
5 cardiovascular disease medical device companies to watch. (Opens in a new window)Here’s a look at five companies in the cardiology treatment and diagnostics space that you may be hearing more about in the years to come.
AstraZeneca, Takeda gout acquisitions make BCRX hopeful for gout drug deal. (Opens in a new window) While the AstraZeneca and Takeda acquisitions likely remove those large pharmas from partnership contention, Stonehouse said the deals also shrink the market for other late-stage gout candidates and make the BioCryst compound more attractive and more valuable.
Covidien discloses $60M purchase of hypertension treatment firm. (Opens in a new window)Covidien announced Tuesday that it will introduce a new renal denervation treatment at a European conference in mid May, but nowhere in the press release does the Massachusetts device firm name the developer of the technology: Maya Medical, based in Campbell, California.